Physician profile
Roger Abiragi
NPI 1841306180
$1,384.95
in general payments reported to CMS, 2019-2025
15 companies · $288 in 2025
The $288 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $113 · 2021: $173 · 2022: $125 · 2023: $128 · 2024: $290 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $224.99 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $212.77 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $201.35 | 2019-2024 | |
| Cranial Technologies, INC | $145.19 | 2019-2025 | Doc Band |
| Pfizer INC. | $131.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $107.91 | 2020-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Sanofi-Aventis U.S. LLC | $93.50 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.81 | 2019-2021 | |
| Tris Pharma INC | $37.87 | 2019 | |
| Kaleo, INC. | $33.70 | 2019-2020 | |
| Adlon Therapeutics L.P. | $33.09 | 2021 | |
| Shire North American Group INC | $28.99 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.98 | 2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $19.93 | 2025 | Neffy, Ragwitek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Abiragi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.